Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Cystectomy
100%
Bladder Cancer
98%
Systematic Review
64%
Prostate Cancer
59%
Prostatectomy
48%
Robot-Assisted Prostatectomy
43%
Biopsy Technique
38%
Neoadjuvant Chemotherapy
37%
Meta-Analysis
32%
Pneumoperitoneum
29%
Muscle Invasive Bladder Cancer
28%
Artificial Intelligence
27%
Biological Marker
27%
Transurethral Resection
26%
Non Muscle Invasive Bladder Cancer
25%
Urologic Surgery
25%
Urinary System
23%
COVID-19
22%
Cystoscopy
21%
Prostate Biopsy
21%
Robot-Assisted Surgery
20%
Arm
20%
Diseases
20%
Bladder
19%
Urology
19%
Overall Survival
18%
Malignant Neoplasm
18%
Clinical Trial
16%
Surgeon
16%
Bladder Tumor
15%
Transitional Cell Carcinoma
15%
Pelvis
15%
Urinary Diversion
14%
Postoperative Pain
14%
Randomized Controlled Trial
14%
Carcinoma in Situ
14%
Microhematuria
14%
Erdafitinib
14%
Urothelial Cancer
13%
Histology
13%
Cancer Specific Survival
13%
Transrectal Ultrasonography
13%
Urinary Tract Infection
13%
Magnetic Resonance Imaging
12%
Adenocarcinoma
12%
Chemotherapy
12%
Da Vinci Surgical System
11%
Infection
11%
Surgical Margin
11%
Bleeding
11%
Keyphrases
Non-muscle Invasive Bladder Cancer (NMIBC)
49%
Radical Cystectomy
32%
Bladder Cancer
28%
Neoadjuvant Chemotherapy
28%
Meta-analysis
22%
95% Confidence Interval
20%
Artificial Intelligence
18%
High Risk
17%
Robot-assisted Radical Cystectomy
17%
Robot-assisted Laparoscopic Radical Prostatectomy
16%
COVID-19
16%
Erdafitinib
14%
Randomized Controlled Trial
12%
Intermediate Risk
12%
Overall Survival
11%
Cystectomy
10%
Bacillus Calmette
10%
Transurethral Resection
10%
Radical Prostatectomy
9%
Prostate Cancer Screening
9%
Urological Surgery
9%
THOR 2
9%
During Pregnancy
9%
Robotic Prostatectomy
9%
Localized Prostate Cancer
8%
Clinical Trials
7%
Prostate-specific Membrane Antigen Positron Emission Tomography
7%
Recurrence-free Survival
7%
Carcinoma in Situ
7%
Pathological Outcomes
7%
Learning Curve
7%
Operative Time
6%
Fibroblast Growth Factor Receptor 3 (FGFR3)
6%
Cystoscopy
6%
Oncologic
6%
Urolithiasis
6%
Prospective Cohort Study
5%
Sepsis
5%
Console Time
5%
Postoperative Complications
5%
Pelvic Lymph Node Dissection
5%
Cisplatin
5%
Prostate
5%
Artificial Intelligence Applications
5%
Nomogram
5%